Pharmacokinetic challenges in renal replacement therapy
Year: 2019
Type: dissertation
Abstract: Patients with end-stage renal disease (ESRD) are treated with renal replacement therapy (RRT), which consist of either dialysis or renal transplantation. Pharmacological therapy is essential for these patients, but can be challenged by adverse events. The overall aim of this thesis was to investigate clinical pharmacokinetics in patients receiving RRT to optimize drug therapy and identify risk factors for inferior long-term outcomes.\nLoss of renal function in patients with ESRD receiving dialysis affects nonrenal drug elimination. The underlying mechanisms for this are largely unknown. This thesis presents a clinical trial were we observed that increasing degree of uremia between dialysis sessions had a direct inhibitory effect on cytochrome P450 3A (CYP3A) enzyme activity in patients receiving hemodialysis. The reduction was not large enough to be clinically relevant for most CYP3A substrate drugs. However, caution is warranted for drugs with narrow therapeutic range in selected patients.\nTacrolimus is currently the foundation of the immunosuppressive regimen after renal transplantation. There is a twentyfold difference in dose needed to reach target exposure due to large pharmacokinetic variability. This thesis presents two large cohort studies were we found that high estimated tacrolimus clearance was significantly associated with risk of acute rejection, as well as development of interstitial fibrosis and tubular atrophy in the kidney graft. The tacrolimus clearance estimate is a simple marker to detect patients at higher risk of early adverse events that can be detrimental for long-term outcomes.\nBelatacept is an immunosuppressive therapeutic protein that can be used as an alternative to tacrolimus. Limited amount of data describing belatacept pharmacokinetics exist, and it is currently unknown if therapeutic monitoring of belatacept can improve clinical outcomes. This thesis presents a clinical feasibility trial were we showed that a novel assay for determination of serum belatacept concentrations performed well. The results signaled that there may be a larger variability in exposure of belatacept than previously described.
Source: NVA (Nasjonalt vitenarkiv)
Author: Erlend Johannessen Egeland
Institution: University of Oslo
Language: English
Subfield: Transplantation
Field: Medicine
Domain: Health Sciences
Keywords: renal replacement therapy, end-stage renal disease, dialysis, kidney transplantation, pharmacokinetics, uremia, CYP3A inhibition, tacrolimus, tacrolimus clearance, acute rejection, interstitial fibrosis and tubular atrophy, belatacept, therapeutic drug monitoring, immunosuppression, drug exposure variability
Open Access status: green
OpenAlex ID: W2971088465
